Activated platelets positively regulate RANKL-mediated osteoclast differentiation

Journal of Cellular Biochemistry

Volumn 102, Issue 5, 2007, Pages 1300-1307

  Weicht, Barbara ^a   Maitz, Philipp ^a   Kandler, Barbara ^a   Fischer, Michael B ^a   Watzek, Georg ^a   Gruber, Reinhard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bone resorption; Inflammation; Mitogen activated protein kinase; Osteoclast; Platelets; Transforming growth factor beta

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; COLONY STIMULATING FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 9; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL COUNT; CELL CULTURE; CELL DIFFERENTIATION; FEMALE; HEMATOPOIETIC CELL; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR AFFINITY; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION;

ACID PHOSPHATASE; ADULT; ANIMALS; BLOOD PLATELETS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL NUCLEUS; CELLS, CULTURED; FEMALE; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MICE; MICE, INBRED STRAINS; OSTEOCLASTS; PLATELET ACTIVATION; PRECIPITIN TESTS; RANK LIGAND; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; THROMBIN; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 36849063220     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21360     Document Type: Article

References (46)

1. Asagiri M, Takayanagi H. 2007. The molecular understanding of osteoclast differentiation. Bone 40:251-264.
2. Blakytny R, Ludlow A, Martin GE, Ireland G, Lund LR, Ferguson MW, Brunner G. 2004. Latent TGF-beta1 activation by platelets. J Cell Physiol 199:67-76.
3. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337-342.
4. Brennan FM, Chantry D, Turner M, Foxwell B, Maini R, Feldmann M. 1990. Detection of transforming growth factor-beta in rheumatoid arthritis synovial tissue: Lack of effect on spontaneous cytokine production in joint cell cultures. Clin Exp Immunol 81:278-285.
5. Chambers TJ. 2000. Regulation of the differentiation and function of osteoclasts. J Pathol 192:4-13.
6. Dittrich M, Birschmann I, Stuhlfelder C, Sickmann A, Herterich S, Nieswandt B, Walter U, Dandekar T. 2005. Understanding platelets. Lessons from proteomics, genomics and promises from network analysis. Thromb Haemost 94:916-925.
7. Endresen GK. 1981. Investigation of blood platelets in synovial fluid from patients with rheumatoid arthritis. Scand J Rheumatol 10:204-208.
8. Endresen GK. 1989. Evidence for activation of platelets in the synovial fluid from patients with rheumatoid arthritis. Rheumatol Int 9:19-24.
9. Farr M, Wainwright A, Salmon M, Hollywell CA, Bacon PA. 1984. Platelets in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int 4:13-17.
10. Fox SW, Lovibond AC. 2005. Current insights into the role of transforming growth factor-beta in bone resorption. Mol Cell Endocrinol 243:19-26.
11. Fuller K, Lean JM, Bayley KE, Wani MR, Chambers TJ. 2000. A role for TGFbeta(1) in osteoclast differentiation and survival. J Cell Sci 113(Pt 13):2445-2453.
12. Gawaz M, Langer H, May AE. 2005. Platelets in inflammation and atherogenesis. J Clin Invest 115:3378-3384.
13. Gruber R, Karreth F, Fischer MB, Watzek G. 2002. Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism. Bone 30:726-732.
14. Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV, Hata K, Yamashita K, Hiraga T, Watanabe T, Kukita T, Yoshioka K, Rao A, Yoneda T. 2004. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 114:475-484.
15. Kacena MA, Nelson T, Clough ME, Lee SK, Lorenzo JA, Gundberg CM, Horowitz MC. 2006. Megakaryocyte-mediated inhibition of osteoclast development. Bone 39:991-999.
16. Kaneda T, Nojima T, Nakagawa M, Ogasawara A, Kaneko H, Sato T, Mano H, Kumegawa M, Hakeda Y. 2000. Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. J Immunol 165:4254-4263.
17. Karsdal MA, Hjorth P, Henriksen K, Kirkegaard T, Nielsen KL, Lou H, Delaisse JM, Foged NT. 2003. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 278:44975-44987.
18. Kawai T, Matsuyama T, Hosokawa Y, Makihira S, Seki M, Karimbux NY, Goncalves RB, Valverde P, Dibart S, Li YP, Miranda LA, Ernst CW, Izumi Y, Taubman MA. 2006. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 169:987-998.
19. Klinger MH, Jelkmann W. 2002. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 22:913-922.
20. Koller M, Hayer S, Redlich K, Ricci R, David JP, Steiner G, Smolen JS, Wagner EF, Schett G. 2005. JNK1 is not essential for TNF-mediated joint disease. Arthritis Res Ther 7:R166-R173.
21. Koseki T, Gao Y, Okahashi N, Murase Y, Tsujisawa T, Sato T, Yamato K, Nishihara T. 2002. Role of TGF-beta family in osteoclastogenesis induced by RANKL. Cell Signal 14:31-36.
22. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. 2000. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106:1481-1488.
23. Lee SE, Woo KM, Kim SY, Kim HM, Kwack K, Lee ZH, Kim HH. 2002. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 30:71-77.
24. Lee SK, Gardner AE, Kalinowski JF, Jastrzebski SL, Lorenzo JA. 2006. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Bone 38(5):678-685.
25. Lerner UH. 1996. Transforming growth factor-beta stimulates bone resorption in neonatal mouse calvariae by a prostaglandin-unrelated but cell proliferation-dependent pathway. J Bone Miner Res 11:1628-1639.
26. Lettesjo H, Nordstrom E, Strom H, Nilsson B, Glinghammar B, Dahlstedt L, Moller E. 1998. Synovial fluid cytokines in patients with rheumatoid arthritis or other arthritic lesions. Scand J Immunol 48:286-292.
27. Macaulay IC, Carr P, Gusnanto A, Ouwehand WH, Fitzgerald D, Watkins NA. 2005. Platelet genomics and proteomics in human health and disease. J Clin Invest 115:3370-3377.
28. Massey HM, Scopes J, Horton MA, Flanagan AM. 2001. Transforming growth factor-beta1 (TGF-beta) stimulates the osteoclast-forming potential of peripheral blood hematopoietic precursors in a lymphocyte-rich microenvironment. Bone 28:577-582.
29. Medicherla S, Ma JY, Mangadu R, Jiang Y, Zhao JJ, Almirez R, Kerr I, Stebbins EG, O'Young G, Kapoun AM, Luedtke G, Chakravarty S, Dugar S, Genant HK, Protter AA. 2006. A Selective p38{alpha} MAPK Inhibitor Reverses Cartilage and Bone Destruction in Mice with Collagen-Induced Arthritis. J Pharmacol Exp Ther 318(1):132-141.
30. Myers SL, Christine TA. 1982. Measurement of beta-thromboglobulin connective tissue activating peptide-III platelet antigen concentrations in pathologic synovial fluids. J Rheumatol 9:6-12.
31. Nakamura H, Hirata A, Tsuji T, Yamamoto T. 2003. Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. J Bone Miner Res 18:1198-1205.
32. Quinn JM, Itoh K, Udagawa N, Hausier K, Yasuda H, Shima N, Mizuno A, Higashio K, Takahashi N, Suda T, Martin TJ, Gillespie MT. 2001. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res 16:1787-1794.
33. Riggs BL, Parfitt AM. 2005. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20:177-184.
34. Schlaak JF, Pfers I, Meyer Zum Buschenfelde KH, Marker-Hermann E. 1996. Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin Exp Rheumatol 14:155-162.
35. Schurigt U, Stopfel N, Huckel M, Pfirschke C, Wiederanders B, Brauer R. 2005. Local expression of matrix metalloproteinases, cathepsins, and their inhibitors during the development of murine antigen-induced arthritis. Arthritis Res Ther 7:R174-R188.
36. Skaleric U, Kramar B, Petelin M, Pavlica Z, Wahl SM. 1997. Changes in TGF-beta 1 levels in gingiva, crevicular fluid and serum associated with periodontal inflammation in humans and dogs. Eur J Oral Sci 105:136-142.
37. Steinberg AD, Alves ME, Lipowski J, Lebreton GC. 1995. Platelet association with gingival tissue inflammation. J Periodontol 66:860-863.
38. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. 1999. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345-357.
39. Takahashi N, Yamana H, Yoshiki S, Roodman GD, Mundy GR, Jones SJ, Boyde A, Suda T. 1988. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 122:1373-1382.
40. Takayanagi H. 2005. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 83:170-179.
41. Teitelbaum SL, Ross FP. 2003. Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-649.
42. Wagner DD, Burger PC. 2003. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 23:2131-2137.
43. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. 2005. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115:282-290.
44. Weyrich AS, Lindemann S, Zimmerman GA. 2003. The evolving role of platelets in inflammation. J Thromb Haemost 1:1897-1905.
45. Yang SY, Mayton L, Wu B, Goater JJ, Schwarz EM, Wooley PH. 2002. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. Arthritis Rheum 46:2514-2523.
46. Zwerina J, Hayer S, Redlich K, Bobacz K, Kollias G, Smolen JS, Schett G. 2006. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum 54:463-472.